Ever since SmithKline Beecham decided not to pursue its interest in the potential migraine treatment frovatriptan, Vanguard Medica Group plc (LSE:VGD) has struggled to convince investors that the compound is a winner. Replacing SmithKline has been even more difficult because VGD has not had many big names to choose from. Instead of going for the top tier pharma companies